Stock Analysis on Net
Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Beginner level

Long-term Activity Ratios (Summary)

Abbott Laboratories, long-term (investment) activity ratios (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Net fixed asset turnover 3.77 4.06 3.97 4.01 3.95 4.03 4.04 4.08 3.98 3.71 3.60 3.48 3.24 3.07 3.66 3.61 3.53 3.49 3.56
Total asset turnover 0.46 0.48 0.47 0.46 0.45 0.45 0.46 0.42 0.43 0.40 0.36 0.35 0.33 0.31 0.40 0.52 0.52 0.51 0.49
Equity turnover 1.03 1.06 1.03 0.99 0.98 0.99 1.00 0.99 0.97 0.91 0.89 0.78 0.75 0.71 1.02 1.00 0.99 0.98 0.96

Based on: 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-06).

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Abbott Laboratories’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Abbott Laboratories’s total asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Abbott Laboratories’s equity turnover ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020 not reaching Q4 2019 level.

Net Fixed Asset Turnover

Abbott Laboratories, net fixed asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Net sales 7,328  7,726  8,314  8,076  7,979  7,535  7,765  7,656  7,767  7,390  7,589  6,829  6,637  6,335  5,333  5,302  5,333  4,885  5,188  5,150  5,170  4,897 
Net property and equipment 8,343  7,907  8,038  7,825  7,825  7,626  7,563  7,448  7,432  7,659  7,607  7,219  7,286  7,265  5,705  5,734  5,826  5,836  5,730  5,797  5,738  5,699 
Long-term Activity Ratio
Net fixed asset turnover1 3.77 4.06 3.97 4.01 3.95 4.03 4.04 4.08 3.98 3.71 3.60 3.48 3.24 3.07 3.66 3.61 3.53 3.49 3.56
Benchmarks
Net Fixed Asset Turnover, Competitors2
AbbVie Inc. 7.38 11.50 11.23 11.36 11.33 11.42 11.36 10.91 11.10 10.47 10.07 10.11 10.05 10.04 9.85 9.57 9.46 9.16 8.91
Amgen Inc. 4.78 4.68 4.51 4.55 4.58 4.59 4.54 4.51 4.48 4.44 4.37 4.45 4.41 4.41 4.41 4.39 4.41 4.36 4.27
Biogen Inc. 4.35 4.39 4.43 4.54 4.57 4.58 3.74 3.74 3.78 3.78 3.86 3.95 4.14 4.42 4.58 4.78 4.88 4.84 4.92
Bristol-Myers Squibb Co. 6.03 5.07 4.18 5.00 4.92 4.67 4.49 4.33 4.25 4.16 4.15 4.10 4.09 3.98 3.90 3.86 3.83 3.80 3.75
Eli Lilly & Co. 2.88 2.92 2.83 2.90 2.96 3.08 2.75 2.75 2.72 2.61 2.59 2.61 2.56 2.56 2.57 2.53 2.55 2.51 2.48
Gilead Sciences Inc. 4.70 4.90 4.91 5.03 5.16 5.31 5.41 5.76 6.23 7.11 7.79 8.72 9.31 9.80 10.45 11.48 12.29 13.34 14.13
Illumina Inc. 3.77 4.00 3.99 3.95 3.99 3.99 3.10 3.06 3.00 2.99 2.96 3.01 2.97 3.30 3.36 3.74 4.52 5.85 6.48
Johnson & Johnson 4.57 4.75 4.65 4.79 4.72 4.80 4.79 4.89 4.85 4.62 4.50 4.47 4.41 4.46 4.52 4.45 4.44 4.40 4.41
Merck & Co. Inc. 2.99 3.15 3.11 3.22 3.20 3.19 3.18 3.27 3.27 3.24 3.23 3.27 3.31 3.32 3.31 3.32 3.29 3.19 3.16
Pfizer Inc. 3.49 3.61 3.71 3.87 3.97 4.00 4.01 3.80 3.83 3.77 3.79 3.89 3.91 3.97 3.97 4.01 3.84 3.75 3.55
Regeneron Pharmaceuticals Inc. 2.64 2.71 2.72 2.75 2.70 2.65 2.61 2.52 2.52 2.53 2.49 2.43 2.32 2.19 2.33 2.53 2.62 2.66 2.57
Vertex Pharmaceuticals Inc. 7.42 6.55 5.59 4.93 4.72 4.40 3.75 3.50 3.21 3.02 3.15 3.02 2.88 2.85 2.44 2.42 2.26 1.87 1.48
Zoetis Inc. 3.15 3.21 3.23 3.39 3.48 3.51 3.51 3.68 3.80 3.75 3.70 3.69 3.70 3.62 3.54 3.53 3.62 3.66 3.65

Based on: 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-06).

1 Q2 2020 Calculation
Net fixed asset turnover = (Net salesQ2 2020 + Net salesQ1 2020 + Net salesQ4 2019 + Net salesQ3 2019) ÷ Net property and equipment
= (7,328 + 7,726 + 8,314 + 8,076) ÷ 8,343 = 3.77

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Net fixed asset turnover An activity ratio calculated as total revenue divided by net fixed assets. Abbott Laboratories’s net fixed asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Total Asset Turnover

Abbott Laboratories, total asset turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Net sales 7,328  7,726  8,314  8,076  7,979  7,535  7,765  7,656  7,767  7,390  7,589  6,829  6,637  6,335  5,333  5,302  5,333  4,885  5,188  5,150  5,170  4,897 
Total assets 68,776  66,777  67,887  68,539  68,427  67,610  67,173  71,637  68,415  70,908  76,250  72,248  71,151  70,887  52,666  39,497  39,831  39,637  41,247  41,725  44,125  43,095 
Long-term Activity Ratio
Total asset turnover1 0.46 0.48 0.47 0.46 0.45 0.45 0.46 0.42 0.43 0.40 0.36 0.35 0.33 0.31 0.40 0.52 0.52 0.51 0.49
Benchmarks
Total Asset Turnover, Competitors2
AbbVie Inc. 0.24 0.37 0.37 0.55 0.57 0.58 0.55 0.49 0.50 0.43 0.40 0.40 0.40 0.40 0.39 0.38 0.37 0.44 0.43
Amgen Inc. 0.36 0.37 0.37 0.37 0.38 0.35 0.34 0.33 0.33 0.31 0.27 0.27 0.28 0.28 0.28 0.28 0.29 0.28 0.29
Biogen Inc. 0.57 0.55 0.53 0.52 0.54 0.52 0.53 0.52 0.54 0.48 0.52 0.51 0.54 0.54 0.50 0.52 0.52 0.53 0.55
Bristol-Myers Squibb Co. 0.27 0.24 0.20 0.42 0.43 0.67 0.64 0.65 0.66 0.64 0.62 0.61 0.61 0.61 0.58 0.55 0.54 0.53 0.52
Eli Lilly & Co. 0.55 0.56 0.57 0.60 0.60 0.63 0.56 0.54 0.56 0.53 0.51 0.52 0.54 0.57 0.55 0.55 0.56 0.58 0.56
Gilead Sciences Inc. 0.39 0.37 0.36 0.37 0.35 0.35 0.34 0.34 0.35 0.37 0.37 0.42 0.47 0.50 0.53 0.55 0.64 0.68 0.62
Illumina Inc. 0.46 0.49 0.48 0.49 0.49 0.46 0.48 0.48 0.53 0.53 0.52 0.51 0.51 0.53 0.56 0.56 0.58 0.59 0.60
Johnson & Johnson 0.51 0.53 0.52 0.53 0.52 0.54 0.53 0.52 0.52 0.50 0.49 0.48 0.47 0.50 0.51 0.51 0.51 0.52 0.53
Merck & Co. Inc. 0.52 0.57 0.55 0.55 0.53 0.52 0.51 0.49 0.49 0.47 0.46 0.43 0.43 0.41 0.42 0.41 0.41 0.40 0.39
Pfizer Inc. 0.28 0.30 0.31 0.31 0.34 0.35 0.34 0.32 0.32 0.32 0.31 0.30 0.31 0.31 0.31 0.30 0.31 0.31 0.29
Regeneron Pharmaceuticals Inc. 0.55 0.51 0.53 0.55 0.55 0.54 0.57 0.59 0.62 0.65 0.67 0.63 0.65 0.64 0.70 0.69 0.75 0.75 0.73
Vertex Pharmaceuticals Inc. 0.53 0.54 0.50 0.48 0.49 0.50 0.49 0.61 0.60 0.61 0.70 0.72 0.65 0.69 0.59 0.64 0.61 0.52 0.41
Zoetis Inc. 0.49 0.55 0.54 0.55 0.55 0.54 0.54 0.55 0.65 0.63 0.62 0.55 0.64 0.65 0.64 0.63 0.65 0.65 0.60

Based on: 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-06).

1 Q2 2020 Calculation
Total asset turnover = (Net salesQ2 2020 + Net salesQ1 2020 + Net salesQ4 2019 + Net salesQ3 2019) ÷ Total assets
= (7,328 + 7,726 + 8,314 + 8,076) ÷ 68,776 = 0.46

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Total asset turnover An activity ratio calculated as total revenue divided by total assets. Abbott Laboratories’s total asset turnover ratio improved from Q4 2019 to Q1 2020 but then deteriorated significantly from Q1 2020 to Q2 2020.

Equity Turnover

Abbott Laboratories, equity turnover calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selected Financial Data (US$ in millions)
Net sales 7,328  7,726  8,314  8,076  7,979  7,535  7,765  7,656  7,767  7,390  7,589  6,829  6,637  6,335  5,333  5,302  5,333  4,885  5,188  5,150  5,170  4,897 
Total Abbott shareholders’ investment 30,578  30,218  31,088  31,817  31,686  30,925  30,524  30,705  30,577  31,399  30,897  32,032  31,602  31,362  20,538  20,776  20,675  20,722  21,211  21,111  23,008  21,874 
Long-term Activity Ratio
Equity turnover1 1.03 1.06 1.03 0.99 0.98 0.99 1.00 0.99 0.97 0.91 0.89 0.78 0.75 0.71 1.02 1.00 0.99 0.98 0.96
Benchmarks
Equity Turnover, Competitors2
AbbVie Inc. 2.46 8.33 5.54 4.08 4.44 5.25 5.53 3.90 4.39 5.12 5.79
Amgen Inc. 2.17 2.41 2.30 2.04 2.07 2.07 1.80 1.54 1.48 1.40 0.86 0.68 0.69 0.71 0.73 0.70 0.72 0.74 0.75
Biogen Inc. 1.28 1.15 1.08 1.02 1.09 1.00 1.03 0.96 1.05 0.90 0.97 0.92 1.01 1.00 0.94 0.94 0.99 1.06 1.15
Bristol-Myers Squibb Co. 0.71 0.62 0.51 1.37 1.49 1.53 1.61 1.62 1.75 1.64 1.77 1.39 1.38 1.38 1.20 1.18 1.18 1.18 1.16
Eli Lilly & Co. 5.61 7.50 8.56 6.69 8.35 9.66 2.50 1.86 2.07 1.61 1.97 1.51 1.56 1.54 1.52 1.34 1.41 1.34 1.37
Gilead Sciences Inc. 1.21 1.01 0.98 1.07 0.97 1.00 1.01 0.96 1.05 1.18 1.26 1.09 1.24 1.40 1.59 1.85 2.06 2.42 1.73
Illumina Inc. 0.73 0.77 0.77 0.78 0.79 0.85 0.89 0.93 0.95 0.98 1.00 0.91 0.92 0.95 1.09 1.06 1.13 1.13 1.20
Johnson & Johnson 1.28 1.35 1.38 1.40 1.34 1.38 1.37 1.26 1.28 1.24 1.27 1.01 1.01 1.03 1.02 0.98 0.98 0.97 0.98
Merck & Co. Inc. 1.71 1.83 1.81 1.71 1.61 1.56 1.58 1.29 1.27 1.21 1.17 1.04 1.01 1.00 0.99 0.91 0.91 0.90 0.88
Pfizer Inc. 0.76 0.78 0.82 0.81 0.90 0.92 0.85 0.75 0.76 0.72 0.74 0.86 0.90 0.90 0.89 0.84 0.83 0.81 0.75
Regeneron Pharmaceuticals Inc. 0.88 0.66 0.71 0.73 0.74 0.73 0.77 0.81 0.86 0.92 0.96 0.91 0.95 1.02 1.09 1.05 1.14 1.18 1.12
Vertex Pharmaceuticals Inc. 0.72 0.75 0.68 0.69 0.68 0.69 0.69 0.97 0.98 1.01 1.23 1.28 1.28 1.35 1.47 1.63 1.59 1.35 1.10
Zoetis Inc. 2.13 2.30 2.31 2.30 2.51 2.55 2.67 2.70 2.84 2.78 3.00 2.58 2.93 3.08 3.29 3.08 3.58 4.14 4.46

Based on: 10-Q (filing date: 2020-07-29), 10-Q (filing date: 2020-04-29), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-10-31), 10-Q (filing date: 2019-07-31), 10-Q (filing date: 2019-05-01), 10-K (filing date: 2019-02-22), 10-Q (filing date: 2018-10-31), 10-Q (filing date: 2018-08-01), 10-Q (filing date: 2018-05-02), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-02), 10-Q (filing date: 2017-08-02), 10-Q (filing date: 2017-05-03), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-03), 10-Q (filing date: 2016-08-03), 10-Q (filing date: 2016-05-04), 10-K (filing date: 2016-02-19), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-04), 10-Q (filing date: 2015-05-06).

1 Q2 2020 Calculation
Equity turnover = (Net salesQ2 2020 + Net salesQ1 2020 + Net salesQ4 2019 + Net salesQ3 2019) ÷ Total Abbott shareholders’ investment
= (7,328 + 7,726 + 8,314 + 8,076) ÷ 30,578 = 1.03

2 Click competitor name to see calculations.

Long-term activity ratio Description The company
Equity turnover An activity ratio calculated as total revenue divided by shareholders’ equity. Abbott Laboratories’s equity turnover ratio improved from Q4 2019 to Q1 2020 but then slightly deteriorated from Q1 2020 to Q2 2020 not reaching Q4 2019 level.